+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis



Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis



Expert Opinion on Drug Safety 15(Sup1): 35-54



Malignancies have been reported in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, treated with anti-tumour necrosis factor (anti-TNF) agents. Areas covered: We conducted a systematic review of randomized controlled trials (RCTs) to determine the effect of anti-TNF agents on the occurrence of cancer (any type). Literature databases were searched up to May 2014 to identify relevant studies that evaluated adalimumab, certolizumab, etanercept, golimumab, or infliximab, compared with placebo or no treatment. Data on cancer occurrence were extracted at the maximum follow-up time reported. Expert opinion: Fifty-five RCTs with 20,631 patients met the eligibility criteria. Of these, 32 trials with 15,539 patients reported at least one case of cancer, for a total of 112 malignancies. The degree of variability between studies was consistent with what would be expected to occur by chance alone. There was no evidence of an association between anti-TNF agents and cancer risk (fixed-effects model (OR: 1.31, 95% CI: 0.89, 1.95); a random-effects model (OR: 1.16, 95% CI: 0.75, 1.81)). We found evidence of selective outcome reporting or publication bias suggesting that the pooled effect estimate for cancer may have been overestimated. The evidence is imprecise, and the risk of bias was high or unclear across primary studies.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 058780758

Download citation: RISBibTeXText

PMID: 27924644

DOI: 10.1080/14740338.2016.1238458


Related references

Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opinion on Drug Safety 15(Sup1): 11-34, 2016

Single-center series and systematic review of randomized controlled trials of malignancies in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis receiving anti-tumor necrosis factor alpha therapy: is there a need for more comprehensive screening procedures?. Arthritis and Rheumatism 61(6): 801-812, 2009

Observational study of switching anti-TNF agents in ankylosing spondylitis and psoriatic arthritis versus rheumatoid arthritis. Wiener Medizinische Wochenschrift 160(9-10): 220-224, 2010

FRI0600Fears and Beliefs of People Living with Rheumatoid Arthritis, Ankylosing Spondylitis or Psoriatic Arthritis: A Systematic Literature Review. Annals of the Rheumatic Diseases 75(Suppl 2): 659.3-660, 2016

FRI0195Treatment with anti-tnf biologics in patient with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis does not increase the risk of malignancy. Annals of the Rheumatic Diseases 72(Suppl 3): A438.1-A438, 2013

Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics. Mediators of Inflammation 2017: 8909834, 2017

Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis. Rmd Open 1(1): E000017, 2015

OP0277Effect of Disease Modifying Drugs on Bone Mineral Density in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis, and Ankylosing Spondylitis: A Meta-Analysis. Annals of the Rheumatic Diseases 73(Suppl 2): 166.2-167, 2014

Do Anti-TNF Blockers Increase the Risk of Lung Involvement in Patients with Ankylosing Spondylitis or Psoriatic Arthritis? A Systematic Review. Israel Medical Association Journal 18(3-4): 154-155, 2016

Serum Sclerostin Levels in Patients with Ankylosing Spondylitis and Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Biomed Research International 2017: 9295313, 2017

Golimumab: a new anti-TNF-alpha agent for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Expert Review of Clinical Immunology 6(5): 721-733, 2010

Anti-rheumatic treatment is not associated with reduction of pentraxin 3 in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Plos one 12(2): E0169830, 2017

Golimumab: A novel anti-TNF-alpha human monoclonal antibody for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Drugs of Today 46(1): 13-22, 2010

Golimumab: A novel human anti-TNF-alpha monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. Core Evidence 4: 159-170, 2010

SAT0108Methotrexate and Anti-TNF Treatment Improve Endothelial Function in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis. Annals of the Rheumatic Diseases 75(Suppl 2): 704.2-704, 2016